

The Academy for Clinical Debates & Controversies in Medicine



CHEP

2ND WORLD CONGRESS ON
**CONTROVERSIES IN THE
MANAGEMENT OF VIRAL HEPATITIS**



BERLIN, GERMANY • OCTOBER 18-20, 2012

1ST ANNOUNCEMENT



www.comtecmed.com/chep • chep@comtecmed.com

Endorsed by





2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS
BERLIN, GERMANY • OCTOBER 18-20, 2012

Dear Friends and Colleagues,

Following the success of the **1st World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)**, we are very pleased to invite you to participate in the **2nd C-Hep Congress** which will be held in Berlin, Germany on October 18-20, 2012.

The large attendance and enthusiastic feedback of the 1st Congress held last May in Barcelona highlighted the need for such a meeting focusing on the needs of the busy clinician caring for HCV and HBV infected patients. The C-Hep Congress attempts to summarize all the key new data recently presented – and how it might be implemented in routine care of Hepatitis B and C patients. Overviews, state of the art lectures and controversial debates with the outstanding faculty of prominent world leaders presenting both pro and con positions challenge and explore the optimal treatment for patients, including the appropriate use of new drugs. This educational Congress focuses on clinical practices in Viral Hepatitis and benefits not only Hepatologists and Infectious Diseases specialist, but also general practitioners, internists and primary care physicians with a desire to gain knowledge in these exciting advances.

The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment.

We look forward to welcoming you at the **2nd C-Hep Congress** in the lovely city of Berlin.

Sincerely,

Jürgen Rockstroh, MD
Germany

Jonathan M. Schapiro, MD
Israel

Co-Chairpersons





2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS
BERLIN, GERMANY • OCTOBER 18-20, 2012

PRELIMINARY SCIENTIFIC PROGRAM

THURSDAY, OCTOBER 18, 2012

HALL A

14:00-16:00	PLENARY SESSION 1 Moderators: Jürgen Rockstroh , <i>Germany</i> ; Jonathan Schapiro , <i>Israel</i>
14:00-14:05	Chairpersons Congress Welcome Address
14:05-14:30	HCV in 2020: Any cases left? Rafael Esteban , <i>Spain</i>
14:30-14:35	Discussion
14:35-15:00	HCV vaccine: Where do we stand? Ulrich Spengler , <i>Germany</i>
15:00-15:05	Discussion
15:05-15:25	Interferon-free HCV therapy: Are we getting there? No: Graham Foster , <i>UK</i>
15:25-15:45	Yes: Heiner Wedemeyer , <i>Germany</i>
15:45-16:00	Discussion
16:00-17:00	TBA
17:00-17:30	<i>Coffee Break and Poster Exhibition</i>
17:30-18:45	TBA
18:45-20:00	Welcome Reception and Poster Prize Ceremony

FRIDAY, OCTOBER 19, 2012

HALL A

09:00-11:00	PLENARY SESSION 2 Moderators: Stefan Zeuzem , <i>Germany</i> ; Eckhard Schott , <i>Germany</i>
09:00-09:05	Overview of HCV sessions by HCV Program Director Stefan Zeuzem , <i>Germany</i>
09:05-09:10	Direct Antivirals: How have the treatment paradigms changed? Moderators Introduction
09:10-09:30	HCV Direct Acting Antivirals: In treatment naïve: Stanislas Pol , <i>France</i>
09:30-09:50	In treatment experienced: Thomas Berg , <i>Germany</i>
09:50-10:10	Toxicity management: Christoph Hezode , <i>Paris</i>
10:10-10:40	Drug-drug interactions: David Back , <i>UK</i>
10:40-11:00	Panel discussion
11:00-11:30	<i>Coffee Break</i>



2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS
BERLIN, GERMANY • OCTOBER 18-20, 2012

PRELIMINARY SCIENTIFIC PROGRAM

FRIDAY, OCTOBER 19, 2012

HALL A		HALL B	
11:30-12:15	SESSION 3 Do we need to know genetic factors such as IL28B for treatment decision making? Yes: Vincent Soriano , <i>Spain</i> No: Mathew Albert , <i>France</i> 11:30-11:45 11:45-12:00 12:00-12:15 Discussion	SESSION 4 HCV therapy is for specialists only? Yes: Marion Peters , <i>USA</i> No: Michael Biermer , <i>Germany</i> Discussion	
12:15-13:00 <i>Lunch Break</i>			
13:00-14:15 TBA			
14:15-15:00	SESSION 5 Patients should wait for DAA combination therapy Yes: Patrick Ingiliz , <i>Germany</i> No: Geoffrey Dusheiko , <i>UK</i> 14:15-14:30 14:30-14:45 14:45-15:00 Discussion	SESSION 6 Resistance to HCV Protease Inhibitors: Game over? Yes: Jean Michel Pawlotsky , <i>France</i> No: Christoph Sarrazin , <i>Germany</i> Discussion	
15:00-15:30	SESSION 7 INTERACTIVE CASE SESSION How to treat HCV relapse after OLTX Raffaele Bruno , <i>Italy</i>	SESSION 8 INTERACTIVE CASE SESSION How to treat HCV in HIV coinfection Stefan Mauss , <i>Germany</i>	
15:30-16:00 <i>Coffee Break</i>			
HALL A			
16:00-17:30	PLENARY SESSION 9		
16:00-16:20	Fatty liver disease: What do we know? Douglas Dieterich , <i>USA</i>		
16:20-16:40	Vitamin D and liver disease: Which role does it play? Christian M. Lange , <i>Switzerland</i>		
16:40-17:00	End-stage liver disease: What is new? Marion Peters , <i>USA</i>		
17:00-17:20	Treatment of HCC: State of the Art Massimo Puoti , <i>Italy</i>		
17:20-17:30	Panel Discussion		



2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS
BERLIN, GERMANY • OCTOBER 18-20, 2012

PRELIMINARY SCIENTIFIC PROGRAM

SATURDAY, OCTOBER 20, 2012

HALL A

- 08:30-10:30** **PLENARY SESSION 10**
HBV THERAPY IN 2012
Moderators: **Fabien Zoulim**, *France*; **Jörg Petersen**, *Germany*
- 08:30-08:35 Overview of HBV sessions by HBV Program Director
Fabien Zoulim, *France*
- 08:35-09:00 Hepatitis B Therapy: State of the Art and open challenges
Jörg Petersen, *Germany*
- 09:00-09:15 Is there a need for combination therapy?
Yes: **Florian van Boemmel**, *Germany*
09:15-09:30 No: **Maria Buti**, *Spain*
- 09:30-09:50 HBV preventive and therapeutic vaccines: What is new?
Marie-Louise Michel, *France*
- 09:50-10:10 Hepatitis Delta: What is new?
Heiner Wedemeyer, *Germany*
- 10:10-10:30 Panel Discussion
- 10:30-11:00** *Coffee Break*
- 11:00-11:45** **PLENARY SESSION 11**
INTERACTIVE CASE SESSION
Moderator: **Fabien Zoulim**, *France*
The challenging hepatitis B case
Mark Nelson, *UK*
Karine Lacombe, *France*
- 11:45-12:45** **PLENARY SESSION 12**
- 11:45-12:00 Strategies to prevent HCC: What can we do?
Mark Thursz, *UK*
- 12:00-12:15 Can we afford HCV DAAs for all?
Maud Lemoine, *France*
- 12:15-12:45 What are the remaining challenges in hepatitis research?
Michael Manns, *Germany*



C-HEP

2ND WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS

BERLIN, GERMANY • OCTOBER 18-20, 2012

THE C-HEP YOUNG INVESTIGATOR POSTER AWARD

We are delighted to announce a special opportunity for young investigators. The C-Hep Young Investigator Poster Exhibition will be held during the C-Hep Congress.

An award will be granted to the winning author. Posters will be evaluated by the C-Hep Awards Committee. First prize will receive 500 Euros and the two runners-up will receive free registration to the 2013 C-Hep conference.

DEADLINE FOR ABSTRACT SUBMISSION:
AUGUST 6, 2012

GENERAL INFORMATION

REGISTRATION

	Early Registration Until August 6, 2012	Late Registration from August 7 until October 9, 2012	From October 10, 2012 and On Site
Participants - Physicians and Scientists	€540	€590	€650
Residents, Nurses, Students	€385	€430	€470

* Note: American Express and Diners Credit card payments (only) will be charged to your account in US\$ according to the rate of exchange to the Euro on the date of payment, all other credit cards will be charged to your account in Euro.

Registration fees include: Participation in scientific sessions, Congress bag, program book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday.

LIABILITY

The Congress Secretariat and Organizers cannot accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep). Participants should make their own arrangements with respect to health and travel insurance.

CONGRESS SECRETARIAT

Please do not hesitate to contact the Secretariat if you require any additional information or assistance. Please address all correspondence to: chep@comtecmed.com



Headquarters and Administration:

53 Rothschild Boulevard
PO Box 68
Tel Aviv 61000, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177
Email: info@comtecmed.com

Comtec Spain:

Bailén, 95-97
pral. 1. a - 08009
Barcelona, Spain
Tel: +34-93-2081145
Fax: +34-93-4579291
Email: spain@comtecmed.com

Comtec China:

175 Xiang Yang Road South
Shanghai 200031
China
Tel: +86-21-54660460
Fax: +86-21-54660450
Email: china@comtecmed.com

www.comtecmed.com/chep • chep@comtecmed.com